Preclinical biopharmaceutical company
Rethinking oral testosterone replacement.
SteroCore Therapeutics is a preclinical biopharmaceutical company developing STC-101, a metabolically activated oral testosterone prodrug designed to address key biological barriers that limit oral testosterone delivery.
STC-101
Liver-activated oral testosterone prodrug
STC-101 is an investigational preclinical compound. Safety and efficacy have not been established.
STC-101
Lead program
Preclinical
Development stage
University of Kansas
Research origin
A liver-activated approach to an old problem.
Testosterone taken by mouth is extensively broken down by the liver before it can reach circulation, which is why most oral formulations have struggled to deliver consistent, predictable exposure. That first-pass metabolism is the central obstacle STC-101 is designed to work with, not around.
Read the full scienceOur approach
Physiology-led design, tested stepwise.
Physiology-led design
The platform is informed by the known metabolic liabilities of testosterone.
Metabolic activation
STC compounds are designed for liver activation and testosterone release.
Stepwise de-risking
Computational, in vitro, and in vivo studies guide analog selection and formulation.
Analog synthesis and in vitro screening
Built at the intersection of pharmacy and drug development.
Michael Hageman, PhD
